J Drugs Dermatol. 2021 Aug 1;20(8):865-867. doi: 10.36849/JDD.6037.
New development of cell-targeted therapies to enable site-specific skin tissue drug delivery may reduce off-target effects, decrease unwanted toxicities, and enhance drug efficacy. These efforts have led to several targeting strategies that modulate active product delivery to include small molecule-, nucleic acid-, peptide-, antibody-, and cell-based strategies. Tissue specific cell-targeting strategies such as these may be useful in cosmetic dermatologic applications.
The aim of this 16-week clinical trial of a skin brightening composition containing melanocyte cell-targeted biodelivery was to assess its effectiveness in restoring the skin complexion evenness by modulating melanocyte activity in a cohort of 50 Fitzpatrick type I–VI subjects with moderate to severe dyspigmentation.
Data from expert grading, skin surface colorimetry, and subject self-assessments reflected significant improvement in facial skin tone as early as 2 weeks after treatment initiation, with continual improvement through week 16. The most dramatic pigmentation improvement, based on investigator assessments, was a statistically significant improvement in skin brightness at week 2 that progressed to week 8 with significant improvement in skin evenness and brightness. By weeks 12 and 16, progressive levels of significant improvement in skin evenness and brightening became apparent. Colorimetry demonstrated progressive improvement in skin dyspigmentation starting at 2 weeks and continuing to week 16. Subject self-assessment data supported similar improvements in skin dyspigmentation.
These results demonstrate the ability of a cell-targeted topical therapy to achieve improvements in skin pigmentation through site-specific suppression of melanocyte activity. J Drugs Dermatol. 2021;20(8):865-867. oi:10.36849/JDD.6037 THIS ARTICLE HAD BEEN MADE AVAILABLE FREE OF CHARGE. PLEASE SCROLL DOWN TO ACCESS THE FULL fTEXT OF THIS ARTICLE WITHOUT LOGGING IN. NO PURCHASE NECESSARY. PLEASE CONTACT THE PUBLISHER WITH ANY QUESTIONS.
新的细胞靶向治疗方法的发展使药物能够在特定部位递送至皮肤组织，这可能会降低脱靶效应、减少不必要的毒性并提高药物疗效。这些努力已经产生了几种靶向策略，包括调节活性产物递送的小分子、核酸、肽、抗体和基于细胞的策略。这些组织特异性细胞靶向策略可能在美容皮肤科应用中有用。
本项为期 16 周的临床试验旨在评估含有黑素细胞靶向生物传递的皮肤增亮组合物在 50 名 Fitzpatrick 类型 I-VI 的中度至重度色素沉着不均的受试者中通过调节黑素细胞活性来恢复皮肤肤色均匀度的有效性。
专家评分、皮肤表面比色和受试者自我评估的数据反映了在治疗开始后 2 周即可显著改善面部肤色，并且在第 16 周时持续改善。根据研究者评估，最显著的色素改善是在第 2 周时皮肤亮度有统计学意义的改善，到第 8 周时皮肤均匀度和亮度有显著改善。到第 12 周和第 16 周，皮肤均匀度和增亮的显著改善水平逐渐提高。比色法显示皮肤色素沉着不均从第 2 周开始逐渐改善，并持续到第 16 周。受试者自我评估数据支持皮肤色素沉着不均的类似改善。
这些结果表明，通过特定部位抑制黑素细胞活性，细胞靶向局部治疗能够改善皮肤色素沉着。
